Identification of Novel integrin antagonists
新型整合素拮抗剂的鉴定
基本信息
- 批准号:8355238
- 负责人:
- 金额:$ 28.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-22 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdhesionsAdultAffectAffinityAgonistAmino AcidsArteriesAspartateAutoimmune DiseasesAutoimmune ProcessBindingBinding SitesBlood PlateletsBlood VesselsC-terminalCell AdhesionCell membraneCell physiologyCellsChronic DiseaseClinical TrialsCoupledCrohn&aposs diseaseCytoskeletonDevelopmentDiseaseDivalent CationsDrug Delivery SystemsEpithelialEvaluationEventExtracellular MatrixFaceFoundationsFreezingGlutamatesGrowthHemorrhageHemostatic AgentsHomingITGAM geneITGB2 geneImmuneImmunityInflammationInflammatoryInjuryIntegrin BindingIntegrin-mediated Cell Adhesion PathwayIntegrinsInvadedIonsKidneyLeadLeukocytesLigand BindingLigandsLigationMediatingMetalsMonoclonal AntibodiesMultiple SclerosisMyocardial InfarctionNatural regenerationNatureNeoplasm MetastasisOutcomeOutcome StudyOxygenParentsPeptidesPharmaceutical ChemistryPharmaceutical PreparationsPhysiologicalPlasmaPlayPropertyReactionRegulationRoleSignal TransductionSiteSolutionsStructureStructure-Activity RelationshipSubgroupSurfaceThrombosisTissuesTranslatingadhesion receptorbasecarboxylatedesignfallsinterdisciplinary approachmimeticsmortalitynovelnovel strategiesnovel therapeuticspathogenpreventreceptorreceptor couplingresponsesmall moleculestructural biologytherapeutic targetvon Willebrand Factor
项目摘要
DESCRIPTION (provided by applicant): Integrins are ¿/¿ heterodimeric adhesion receptors that play essential roles in kidney formation during development and in regeneration of the adult kidney following inflammatory or vascular injury. Abnormal integrin function can lead, however, to inflammatory, autoimmune and thrombotic disorders affecting the kidney and the vasculature, thus making integrins important therapeutic targets. Existing ligand-mimetic monoclonal antibodies (mAbs) and small molecules (fashioned based on structures of natural ligands) exert agonist-like properties, by engaging the integrin ligand binding site, like the parent physiologic ligand, thus inducing cell adhesion responses these drugs were designed to prevent, and underscoring the need for novel approaches targeting integrins in disease. Integrins comprise two subgroups, depending on the presence or absence of a von Willebrand's Factor Type A-domain (vWFA) (¿A- or I domain) found in one-half of the integrin ¿-subunits. ¿A mediates Mg2+- dependent binding of an aspartate (Asp) or glutamate (Glu) residue from integrin ligands (or ligand-mimetic drugs) at a metal-ion-dependent-adhesion site (MIDAS) in ¿A. ¿A-lacking integrins bind ligands through an ¿A-like domain (¿A or I-like) present in their ¿-subunits. The ligand Asp/Gu binds the Mg2+ at MIDAS monodentately, completing an octahedral coordination sphere around the metal ion. Formation of the Mg2+- Asp (or Glu) bond triggers activating conformational changes in the integrin leading to cell adhesion, accounting for the agonist-like properties of existing integrin antagonists. In solving the crystal structure of a ligand-mimetic mAb, which binds at MIDAS in the ¿A domain but prevents conformational switching in the integrin (i.e. acting as a pure antagonist), we found that a Ca2+ is heptacoordinated at MIDAS, the result of the unusual symmetric bidentate ligation by the mAb-derived Asp. Stable heptacoordination of Ca2+ blocked the conformational switching normally induced by ligand occupancy of MIDAS. We hypothesize that it should therefore be feasible to design structure-based cyclized peptide antagonists to the ¿A domain based on our crystal structure, and that switching ligand Asp coordination from the monodentate to the bidentate binding mode in the ¿A MIDAS, thus stabilizing a Ca2+ there, will also achieve a similar outcome in the ¿A-lacking integrins. The present proposal represents a multidisciplinary approach with participation by cell-, structural biology and medicinal chemistry groups. An outcome from these studies will be the development of new probes for assessing structure-activity relationships of these dynamic receptors and could provide new therapeutic strategies to treat a wide-spectrum of disease states affecting the kidney and the vasculature.
PUBLIC HEALTH RELEVANCE: Improper activation of integrins plays critical roles in a diverse range of diseases including inflammatory, autoimmune diseases of the kidney and the vasculature as well as cancer metastasis. Current drugs targeting these receptors have contributed to adverse autoimmune reactions and to increased mortality, the result of inadvertent activation of integrins. Identifying drugs that maintain the integrin in the inactive state is highly desirable and is the subject of this proposal.
描述(由申请人提供):整合素是异二聚体粘附受体,在肾脏发育过程中以及炎症或血管损伤后成人肾脏的再生中发挥重要作用。然而,整合素功能异常可导致影响肾脏和脉管系统的炎症、自身免疫和血栓性疾病,因此整合素成为重要的治疗靶点。现有的拟配体单克隆抗体(mab)和小分子(基于天然配体的结构)通过结合整合素配体结合位点(如亲本生理配体)发挥激动剂样特性,从而诱导细胞粘附反应,这些药物被设计用于预防,并强调需要针对疾病中的整合素的新方法。整合素包括两个亚群,这取决于在一半的整合素亚基中发现的血管性血友病因子类型a结构域(vWFA)(¿a -或I结构域)的存在与否。¿A介导整合素配体(或配体模拟药物)的天冬氨酸(Asp)或谷氨酸(Glu)残基在¿A的金属离子依赖粘附位点(MIDAS)的Mg2+依赖性结合。缺乏A的整合素通过其亚基中存在的A样结构域(A或i样)与配体结合。配体Asp/Gu在MIDAS单齿结合Mg2+,在金属离子周围形成八面体配位球。Mg2+- Asp(或Glu)键的形成触发激活整合素的构象变化,导致细胞粘附,这解释了现有整合素拮抗剂的激动剂样特性。在解拟配体单抗的晶体结构时,我们发现Ca2+在MIDAS是七配位的,这是单抗衍生的Asp不寻常的对称双齿连接的结果。Ca2+的稳定七配位阻断了MIDAS通常由配体占用引起的构象转换。因此,我们假设,基于我们的晶体结构设计基于结构的环化肽拮抗剂应该是可行的,并且在A MIDAS中将配体Asp从单齿结合模式切换到双齿结合模式,从而稳定Ca2+,也将在缺乏A的整合素中实现类似的结果。目前的建议代表了一个多学科的方法与参与细胞,结构生物学和药物化学组。这些研究的结果将是开发新的探针来评估这些动态受体的结构-活性关系,并可能为治疗影响肾脏和脉管系统的各种疾病状态提供新的治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
M. AMIN ARNAOUT其他文献
M. AMIN ARNAOUT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('M. AMIN ARNAOUT', 18)}}的其他基金
Targeting innate immunity for induction of robust renal allograft tolerance
针对先天免疫诱导强大的肾同种异体移植耐受
- 批准号:
10622050 - 财政年份:2023
- 资助金额:
$ 28.09万 - 项目类别:
Effects of combining anti-CD40 and anti-CD11b mAb107 on survival of pig kidney xenografts in cynomolgus monkeys
抗CD40和抗CD11b mAb107联合使用对食蟹猴猪肾异种移植物存活的影响
- 批准号:
10425736 - 财政年份:2022
- 资助金额:
$ 28.09万 - 项目类别:
Effects of combining anti-CD40 and anti-CD11b mAb107 on survival of pig kidney xenografts in cynomolgus monkeys
抗CD40和抗CD11b mAb107联合使用对食蟹猴猪肾异种移植物存活的影响
- 批准号:
10618872 - 财政年份:2022
- 资助金额:
$ 28.09万 - 项目类别:
Platelet alphaIIbbeta3 activation and its therapeutic targeting
血小板αIIbbeta3激活及其治疗靶向
- 批准号:
10469477 - 财政年份:2019
- 资助金额:
$ 28.09万 - 项目类别:
Platelet alphaIIbbeta3 activation and its therapeutic targeting
血小板αIIbbeta3激活及其治疗靶向
- 批准号:
10251142 - 财政年份:2019
- 资助金额:
$ 28.09万 - 项目类别:
Platelet alphaIIbbeta3 activation and its therapeutic targeting
血小板αIIbbeta3激活及其治疗靶向
- 批准号:
10004711 - 财政年份:2019
- 资助金额:
$ 28.09万 - 项目类别:
Role of integrin CD11b in delayed graft function and allorejection
整合素 CD11b 在移植物功能延迟和同种异体排斥中的作用
- 批准号:
9809349 - 财政年份:2019
- 资助金额:
$ 28.09万 - 项目类别:
Structure and Function of Integrins in the Kidney
肾脏中整合素的结构和功能
- 批准号:
10375579 - 财政年份:2010
- 资助金额:
$ 28.09万 - 项目类别:
Structure and function of integrins in the kidney
肾脏整合素的结构和功能
- 批准号:
9354435 - 财政年份:2010
- 资助金额:
$ 28.09万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 28.09万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 28.09万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 28.09万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 28.09万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 28.09万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 28.09万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 28.09万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 28.09万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 28.09万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 28.09万 - 项目类别:














{{item.name}}会员




